{"schema_version":"secwatch.filing_event.v1","accession":"0001601830-24-000035","form_type":"8-K","ticker":"RXRX","cik":"0001601830","company_name":"RECURSION PHARMACEUTICALS, INC.","filed_at":"2024-04-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.170303+00:00","generated_at":"2026-06-03T22:15:28.900468+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Recursion appoints Najat Khan as Chief R&D and Commercial Officer, joins board","bullets":["Dr. Khan appointed Chief R&D Officer and Chief Commercial Officer; also elected Class II Director with term through 2026.","Compensation: base salary $570k, target bonus 50% of base, sign-on bonus $500k, initial equity grant $8M (half RSUs, half options, 4-yr vest).","Previously Chief Data Science Officer at J&J; will lead R&D and build commercial capabilities at Recursion.","Board expanded from 8 to 9 members; no related-party transactions requiring disclosure."],"urls":{"canonical":"https://secwatch.observer/filing/0001601830-24-000035","json":"https://secwatch.observer/filing/0001601830-24-000035.json","markdown":"https://secwatch.observer/filing/0001601830-24-000035.md","text":"https://secwatch.observer/filing/0001601830-24-000035.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1601830/000160183024000035/0001601830-24-000035-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1601830/000160183024000035/rxrx-20240415.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T22:15:28.900468+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"578757b84f","claim":"Najat Khan was elected as Class II Director at RECURSION PHARMACEUTICALS, INC..","evidence_excerpt":"increased the number of members of the Board from 8 to 9 and elected Najat Khan, Ph.D., as a Class II Director of the Board, effective April 16, 2024","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1601830/000160183024000035/0001601830-24-000035-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"elected"},{"label":"Role","value":"Class II Director"}],"fact_type":"executive_change"},{"claim_id":"e20ef90dea","claim":"Najat Khan was appointed as Chief Research and Development Officer and Chief Commercial Officer at RECURSION PHARMACEUTICALS, INC..","evidence_excerpt":"On April 16, 2024, the Company announced that Dr. Khan will be its Chief Research and Development Officer and Chief Commercial Officer, effective upon commencement of her employment with the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1601830/000160183024000035/0001601830-24-000035-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Research and Development Officer and Chief Commercial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}